ABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
